Positive Clinical Trial Results Presented at ASN Kidney Week 2026
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Positive interim results from a Phase 3 clinical trial evaluating a tissue engineered vessel were presented at the American Society of Nephrology’s Kidney Week 2026 in Denver, Colorado. The trial showed that women implanted with the vessel achieved functional access significantly faster than those with an arteriovenous fistula. Recipients of the vessel also averaged more catheter-free days in the first year compared to the fistula group, according to the report.
From manilatimes.net
Why it matters
The successful trial results suggest a potentially meaningful new treatment option for end-stage kidney disease patients. The American Society of Nephrology and Medicare are already collaborating to develop new care models, and this research could influence future treatment standards and associated healthcare costs.
From manilatimes.net
Who's involved
- American Society of NephrologyOrganization that hosted the conference and is collaborating with Medicare on care models.
- Hansa BiopharmaCompany that presented clinical data at the American Society of Nephrology conference.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Hansa BiopharmaSpeculative
Hansa Biopharma could see changes in investment or contracts as the medical industry evaluates new treatment standards.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.How it developed
Newest first. Tap a step to see who reported it.- Climb Bio presented clinical data at ASN Kidney Week 2026 in Denver, Colorado.Sub-event
ASN Kidney Week 2026 conference took place in Denver.1 source
Keep exploring
The entities involved
-
American Society of Nephrology
organization
Nothing else this week.